IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, May 14, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (
NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
IMMUNITYBIO, INC. INVESTORS WITH LOSSES HAVE UNTIL MAY 26, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces DeadlineNEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (
NASDAQ: IBRX) investors of the May 26, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.
ImmunityBio, Inc. (IBRX) Action Lawsuit: Investors Face May 26, 2026, DeadlineSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCNEW YORK CITY and NEW ORLEANS, May 12, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBiopurchased or otherwise acquired the Company’s securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRXNEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (
NASDAQ: IBRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (
NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, inclusive.
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Who Have Suffered Losses - Contact Kaplan Fox before May 26, 2026 Lead Plaintiff DeadlineSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Who Have Suffered Losses - Contact Kaplan Fox before May 26, 2026 Lead Plaintiff DeadlineNEW YORK, NY - May 11, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (
NASDAQ: IBRX) on behalf of investors that purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026 (the “Class Period”).
ImmunityBio, Inc. Investors: May 26, 2026, Deadline in Securities Fraud Class Action LawsuitSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, May 11, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (
NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action LawsuitSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
INVESTOR DEADLINE REMINDER: ImmunityBio, Inc. (IBRX) Investors With Substantial Losses Have Opportunity to Lead Class Action LawsuitSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Securities Class Action Deadline Against ImmunityBio, Inc. (NASDAQ: IBRX) - Contact Kaplan Fox Before May 26, 2026Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Securities Class Action Deadline Against ImmunityBio, Inc. (NASDAQ: IBRX) - Contact Kaplan Fox Before May 26, 2026NEW YORK, NY - May 9, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (
NASDAQ: IBRX) on behalf of investors that purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026 (the “Class Period”).
IMMUNITYBIO CLASS ACTION DEADLINE: Kaplan Fox Encourages ImmunityBio, Inc. (NASDAQ: IBRX) Investors to Contact the Firm Before the Lead Plaintiff Deadline on May 26, 2026NEW YORK, NY - May 8, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (
NASDAQ: IBRX) on behalf of investors that purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026 (the “Class Period”).
Deadline is May 26, 2026 to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX) - Contact Kaplan FoxSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
